Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin (NCT02696044) | Clinical Trial Compass
UnknownPhase 2
Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin
United States12 participantsStarted 2016-06
Plain-language summary
The aim of this study is to evaluate the safety and tolerability of triheptanoin in participants with Rett syndrome using laboratory values, electrocardiogram, rate of adverse events (AE), and physical exam.This study also seeks to evaluate the efficacy of UX007 (triheptanoin) in improving overall seizure frequency and dystonia.
Who can participate
Age range2 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosis of Classic Rett syndrome as defined by the clinical consensus criteria
* Presence of a MECP2 mutation
* Post-regression stage of development, defined as greater than 6 months since the last loss of hand use or verbal language
* Average of at least 4 observable seizures (generalized or partial-onset \[Generalized Tonic-Clonic, Generalized Tonic, Generalized Clonic, Generalized Atonic, Partial/Focal with Secondary Generalization, Myoclonic, Myoclonic Atonic, Myoclonic Tonic, Complex Partial/Focal, and Simple Partial/Focal Motor) in one month prior to the study by caregiver report or presence of dystonia on average at least four times in one month prior to the study in at least one body region rated as at least "mild" by caregiver report
* Use of at least one anti-seizure medication at screening visit
* At screening visit, managed on four or fewer concomitant anti-seizure medications that must have been stable in dose at least one month prior to the beginning of screening and anticipated to remain stable in dose through the end of the 8.5 month trial period
* Legally authorized caregiver must be willing to give written informed consent after the nature of the study has been explained, and prior to any research-related procedures
* Caregiver and participant must, in the opinion of the investigator, be willing and able to complete all aspects of the study, comply with accurate completion of the seizure and dystonia diaries, and be likely to complet…
What they're measuring
1
Change in Clinical Seizure Frequency
Timeframe: Visit 2, Visit 7 (Up to 4 months)
2
Change in Dystonia frequency
Timeframe: Visit 2, Visit 7 (Up to 4 months)
Trial details
NCT IDNCT02696044
SponsorCenter for Rare Neurological Diseases, Norcross, GA